NASDAQ: EXOZExozymes Inc Stock
$11.00+0.00 (+0%)
Updated Apr 30, 2025
EXOZ Price
$11.00
Fair Value Price
$1.03
Market Cap
$92.05M
52 Week Low
$8.50
52 Week High
$23.99
P/E
-12.36x
P/B
8.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$9M
Beta
0.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EXOZ Overview
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EXOZ's potential to beat the market
- EXOZ doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EXOZ
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important EXOZ news, forecast changes, insider trades & much more!
EXOZ News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EXOZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EXOZ ($11.00) is overvalued by 972.92% relative to our estimate of its Fair Value price of $1.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EXOZ ($11.00) is not significantly undervalued (972.92%) relative to our estimate of its Fair Value price of $1.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EXOZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EXOZ due diligence checks available for Premium users.
Valuation
EXOZ fair value
Fair Value of EXOZ stock based on Discounted Cash Flow (DCF)
Price
$11.00
Fair Value
$1.03
Overvalued by
972.92%
EXOZ ($11.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EXOZ ($11.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EXOZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EXOZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.36x
Industry
-162.28x
Market
29.18x
EXOZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.83x
Industry
4.45x
EXOZ is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EXOZ's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.8M
Profit Margin
0%
EXOZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.0M
Liabilities
$2.6M
Debt to equity
0.25
EXOZ's short-term assets ($10.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EXOZ's short-term assets ($10.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EXOZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
-$210.4k
Financing
$15.4M
EXOZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EXOZ vs Biotech Stocks
Exozymes Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.